Skip to Main Content
Phase COVID-II

Self-Management Strategy for Chronic Illness in Stable Heart Failure

  • Study HIC#:0904005041
  • Last Updated:07/15/2021

Chronic insomnia may contribute to the development and exacerbation of heart failure (HF), incident mortality and contributes to common and disabling symptoms (fatigue, dyspnea, anxiety, depression, excessive daytime sleepiness, and pain) and decrements in objective and subjective functional performance.

The purposes of the study are to evaluate the sustained effects of CBT-I on insomnia severity, sleep characteristics, daytime symptoms, and functional performance over twelve months among patients who have stable chronic HF and chronic insomnia. The effects of the treatment on outcomes of HF (hospitalization, death) and costs of the treatment will also be examined.

A total of 200 participants will be randomized to 4 bi-weekly group sessions of cognitive behavioral therapy for CBT-I (behavioral was to improve insomnia and sleep) or HF self-management education.

Participants will complete wrist actigraph (wrist-watch like accelerometer) measures of sleep, diaries, reaction time, and 6 minute walk test distance. They will also complete self-report measures of insomnia, sleep, symptoms, and functional performance. In addition the effects on symptoms and function over a period of one year.

  • Age18 years and older
  • GenderBoth
  • Start Date05/25/2015
  • End Date06/29/2019

Trial Purpose and Description

The purposes of this two group randomized controlled trial (RCT) are to test the sustained effects of cognitive behavioral therapy for insomnia (CBT-I), compared with heart failure (HF) self-management education (attention control) on insomnia severity, objective an subjective sleep characteristics, daytime symptoms, functional performance, and health care utilization over twelve months among patients who have stable HF and chronic comorbid insomnia. We will also explore the effects of CBT-I on event-free survival.

We will address the following specific aims (*primary outcomes):

(1) Test the sustained effects (baseline ¿ 2 weeks, 6, 9, 12 months) of CBT-I provided in 4 group sessions over 8 weeks, compared with HF self-management education (attention control condition), on: (1a) *insomnia severity and self-reported and actigraph-recorded sleep characteristics (*sleep quality, *sleep efficiency, sleep latency, and duration); (1b) symptoms (*fatigue, anxiety, depression, pain, dyspnea, sleepiness, sleep-related impairment), and psychomotor vigilance (PVT); and (1c) symptom clusters [membership in clusters characterized by severity of specific symptoms; transition between clusters over time]; (2) Test the sustained effects of CBT-I on self-reported and objective functional performance; and (3) Examine the cost-effectiveness of CBT-I. Exploratory aim: We will explore the effects of CBT-I on event-free survival.

Hypotheses: CBT-I, compared with an attention-control condition (HF self-management education), leads to: (1a) decreased insomnia severity and sleep latency and increased sleep quality, duration and efficiency that are sustained at 6, 9 and 12 months; (1b) decreases in severity of symptoms and improvements in psychomotor vigilance that are sustained at 6, 9 and 12 months; and 1c) transition between symptom clusters that have higher symptom severity to those that have lower symptom severity over time. (2) CBT-I will lead to increased self-reported and objective functional performance; (3) CBT-I is cost-effective, compared with HF self-management education alone.

Eligibility Criteria

Inclusion Criteria:

  • stable chronic heart failure, chronic insomnia, English speaking/reading,

Exclusion Criteria:

  • untreated sleep disordered breathing or restless legs syndrome, rotating/night shift work, active illicit drug use, bipolar disorder, neuromuscular conditions affecting the non-dominant arm end-stage renal failure, significant cognitive impairment, unstable medical or psychiatric disorders

Principal Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: